SMMT - Summit Therapeutics' Ivonescimab: Strong Buy Its Dual-Action Approach To Cancer
2024-05-06 11:02:30 ET
Summary
- Summit Therapeutics specializes in developing innovative therapeutic solutions for oncology and infectious diseases.
- Their flagship drug candidate, Ivonescimab, is in phase 3 clinical trials and shows promise in treating non-small cell lung cancer.
- The company's Ivonescimab, a bispecific antibody, is supported by a partnership with Akeso. Ivonescimab targets PD-1 and VEGF pathways, potentially treating NSCLC and other cancers.
- Summit’s promising clinical trials, HARMONi and HARMONi-3, focus on advanced lung cancers and aim for FDA approval.
- SMMT is a strong buy because of ivonescimab’s potential in oncology and the company’s proven leadership under Robert Duggan.
...
Summit Therapeutics' Ivonescimab: Strong Buy Its Dual-Action Approach To Cancer